The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.

C.J. Hoekstra; SG Stroobants; O.S. Hoekstra; J Vansteenkiste; B. Biesma; FJ Schramel; N. van Zandwijk; H. van Tinteren; E.F. Smit

doi:https://doi.org/10.1016/S0169-5002(02)00446-4

The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.

C.J. Hoekstra, SG Stroobants, O.S. Hoekstra, J Vansteenkiste, B. Biesma, FJ Schramel, N. van Zandwijk, H. van Tinteren, E.F. Smit

VU University medical center

Research output: Contribution to journal › Article* › Academic › peer-review

Original language	English
Pages (from-to)	151-7
Journal	Lung Cancer
Volume	39
Issue number	2
DOIs	https://doi.org/10.1016/S0169-5002(02)00446-4
Publication status	Published - 2003

Access to Document

https://doi.org/10.1016/S0169-5002(02)00446-4

Cite this

Hoekstra, C. J., Stroobants, SG., Hoekstra, O. S., Vansteenkiste, J., Biesma, B., Schramel, FJ., van Zandwijk, N., van Tinteren, H., & Smit, E. F. (2003). The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer, 39(2), 151-7. https://doi.org/10.1016/S0169-5002(02)00446-4

Hoekstra, C.J. ; Stroobants, SG ; Hoekstra, O.S. ; Vansteenkiste, J ; Biesma, B. ; Schramel, FJ ; van Zandwijk, N. ; van Tinteren, H. ; Smit, E.F. / The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. In: Lung Cancer. 2003 ; Vol. 39, No. 2. pp. 151-7.

@article{93fba943e9e6467dbd64fc1b34065e27,

title = "The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.",

author = "C.J. Hoekstra and SG Stroobants and O.S. Hoekstra and J Vansteenkiste and B. Biesma and FJ Schramel and {van Zandwijk}, N. and {van Tinteren}, H. and E.F. Smit",

year = "2003",

doi = "https://doi.org/10.1016/S0169-5002(02)00446-4",

language = "English",

volume = "39",

pages = "151--7",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

Hoekstra, CJ, Stroobants, SG, Hoekstra, OS, Vansteenkiste, J, Biesma, B, Schramel, FJ, van Zandwijk, N, van Tinteren, H & Smit, EF 2003, 'The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.', Lung Cancer, vol. 39, no. 2, pp. 151-7. https://doi.org/10.1016/S0169-5002(02)00446-4

The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. / Hoekstra, C.J.; Stroobants, SG; Hoekstra, O.S.; Vansteenkiste, J; Biesma, B.; Schramel, FJ; van Zandwijk, N.; van Tinteren, H.; Smit, E.F.

In: Lung Cancer, Vol. 39, No. 2, 2003, p. 151-7.

Research output: Contribution to journal › Article* › Academic › peer-review

TY - JOUR

T1 - The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.

AU - Hoekstra, C.J.

AU - Stroobants, SG

AU - Hoekstra, O.S.

AU - Vansteenkiste, J

AU - Biesma, B.

AU - Schramel, FJ

AU - van Zandwijk, N.

AU - van Tinteren, H.

AU - Smit, E.F.

PY - 2003

Y1 - 2003

U2 - https://doi.org/10.1016/S0169-5002(02)00446-4

DO - https://doi.org/10.1016/S0169-5002(02)00446-4

M3 - Article*

VL - 39

SP - 151

EP - 157

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -